AD, Alzheimer Disease, Cognitive Impairment, Dementia Alzheimers, Dementia, Mild, Dementia Moderate, Dementia of Alzheimer Type, Mild Cognitive Impairment
Conditions
Keywords
Gamma Stimulation, Cognito
Brief summary
This is an open-label extension for a multicenter, randomized, double-blind, sham-controlled, adaptive design pivotal study. Participants who complete the Hope Study (CA-0011) will be eligible to consent for screening to enroll in the OLE Hope Study (CA-0015). All participants will be treated with an Active Sensory Stimulation System (GS120) for 60 minutes daily for up to 12 months. There will be no Sham treatment group or randomization involved in this study.
Detailed description
This is an open-label extension for a multicenter, randomized, double-blind, sham-controlled, adaptive design pivotal study. Participants who complete the Hope Study (CA-0011) will be eligible to consent for screening to enroll in the OLE Hope Study (CA-0015). All participants will be treated with an Active Sensory Stimulation System (GS120) for 60 minutes daily for up to 12 months. There will be no Sham treatment group or randomization involved in this study. Up to approximately 402 participants will complete the Hope Study and be offered participation in the OLE Hope Study at up to approximately 70 clinical sites. The objective of the study will be to assess efficacy of gamma sensory stimulation (visual and audio) in slowing disease progression in the Active-Active group versus Active-Sham group for subjects with mild to moderate AD as measured functionally by the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) assessment and a combined statistical test (CST) for ADCS-ADL and the Mini-Mental State Exam (MMSE). Participants will be treated with the Sensory Stimulation System (GS120) for 60 minutes daily for up to 12 months with Active device settings. Each participant will be involved in the study for up to 13 months: approximately 12 months of treatment and 1 month of safety follow-up.The visits in the study include: a Screening/Enrollment visit (Day 0), followed by telephone training on device receipt, a clinic visit at 12 months and a telephone visit at 6 and 13 months.
Interventions
DEVICESensory Stimulation System (GS120) - Active
Sensory Stimulation System (GS120) - Active settings
Sponsors
Cognito Therapeutics, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is an Open-Label Extension of a previous randomized, sham-controlled study. All subjects in this study will receive treatment with a device with Active treatment settings. Analysis is planned to compare Active-Active treatment group to Sham-Active treatment group (delayed start model).
Eligibility
Sex/Gender
ALL
Age
50 Years to 92 Years
Healthy volunteers
No
Inclusion criteria
* Randomized and completed 12-months of participation in the Hope Study (CA-0011) * Non-childbearing potential or using adequate birth control * Available/consenting Study Partner
Exclusion criteria
* Insufficient adherence to treatment in the Hope Study (CA-0011) * Living in continuous care nursing home (assisted living permitted) * Initiating or ongoing treatment with any of the following during study participation: * Immunomodulators or passive immunotherapies for AD (ie, monoclonal antibodies) * Memantine (Namenda or Namzaric) * Nootropic drugs except stable acetylcholinesterase inhibitors For more information about the Hope Study (CA-0011) that participants in this study complete first, please see: https://www.hopestudyforad.com/ or the Hope Study ClinicalTrials.gov posting here: https://clinicaltrials.gov/study/NCT05637801
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) at 12-Months | Assessed for endpoint at Screening/Baseline and 12-Month clinic visits | Function as measured by the ADCS-ADL (total score possible from 0-78, where a lower score is more affected by Alzheimer's disease) |
| Change from Baseline in a Combined Statistical Test (CST) that creates a composite measure (combining Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) and Mini-Mental State Exam (MMSE) scales into one measure) at 12-Months | Assessed for endpoint at Screening/Baseline and 12-Month clinic visits | Function and Cognition as measured by CST of ADCS-ADL and MMSE (ADCS-ADL total score possible from 0-78, where a lower score is more affected by Alzheimer's disease) (MMSE total score possible from 0-30, where a lower score is more affected by Alzheimer's disease) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Key Secondary: Change from Baseline in Mini-Mental State Exam (MMSE) at 12 Months | Assessed for endpoint at Screening/Baseline and 12-Month clinic visits | Cognition as measured by MMSE (total score possible from 0-30, where a lower score is more affected by Alzheimer's disease) |
Countries
United States
Outcome results
None listed